News about "Dr. Zhou Hui"

Innovent Doses First Patient in Phase III Trial of IBI354 for First-Line HER2-Positive Advanced Breast Cancer

Innovent Doses First Patient in Phase III Trial of IBI354 for First-Line HER2-Positive Advanced Breast Cancer

HeriCare-Breast01 study evaluates next-generation HER2 ADC against standard THInnovent BiologicsP regimen, following promising phase I/II efficacy and safety data presented at ASCO 2025.

Dr. Zhou Hui | 16/02/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members